HOUSTON, Feb. 8, 2024 /PRNewswire/ — FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of…
FibroBiologics Announces Three United States Patents for Fibroblast Technology
This post was originally published on this site